Tectonic Therapeutic (TECX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $20.65, -3.05% vs the prior close of $21.30.
- Volume 175.42K shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
TECX slides 3.1% to $20.65, a 6-month low. Closed at $20.65, -3.05% vs the prior close of $21.30. Day range $20.55–$21.51, opened at $21.35.
TECX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — TECX slides 3.1% to $20.65, a 6-month low
- Closed at $20.65, -3.05% vs the prior close of $21.30. Day range $20.55–$21.51, opened at $21.35.
- Volume was 175.42K shares, 0.8x its 50-day average of 233.82K.
- Price is -28.2% vs its 50-day average ($28.76) and -26.4% vs its 200-day average ($28.07).
- 52-week range $15.52–$39.53; today's close sits at 21% of that range, 47.8% below the 52-week high.
Oct 15, 2026 — TECX rises 1.6% to $21.30
- Closed at $21.30, +1.62% vs the prior close of $20.96. Day range $21.06–$21.51, opened at $21.08.
- Volume was 187.40K shares, 0.8x its 50-day average of 232.59K.
- Price is -26.4% vs its 50-day average ($28.95) and -24.1% vs its 200-day average ($28.08).
- 52-week range $15.52–$39.53; today's close sits at 24% of that range, 46.1% below the 52-week high.
Oct 14, 2026 — TECX dips 1.6% to $20.96, a 6-month low, 3 down days in a row
- Closed at $20.96, -1.64% vs the prior close of $21.31. Day range $20.60–$21.75, opened at $21.22.
- Volume was 190.80K shares, 0.8x its 50-day average of 231.69K.
- Price is -28.0% vs its 50-day average ($29.12) and -25.3% vs its 200-day average ($28.07).
- 52-week range $15.45–$39.53; today's close sits at 23% of that range, 47.0% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — TECX slides 4.7% to $21.31, a 6-month low
- Closed at $21.31, -4.65% vs the prior close of $22.35. Day range $21.02–$22.38, opened at $22.23.
- Volume was 164.00K shares, 0.7x its 50-day average of 230.53K.
- Price is -27.2% vs its 50-day average ($29.28) and -24.1% vs its 200-day average ($28.07).
- 52-week range $15.45–$39.53; today's close sits at 24% of that range, 46.1% below the 52-week high.
Oct 12, 2026 — TECX slides 4.2% to $22.35, a 6-month low
- Closed at $22.35, -4.20% vs the prior close of $23.33. Day range $22.26–$23.12, opened at $22.99.
- Volume was 103.90K shares, 0.4x its 50-day average of 233.51K — lighter than usual.
- Price is -24.0% vs its 50-day average ($29.42) and -20.4% vs its 200-day average ($28.07).
- 52-week range $15.45–$39.53; today's close sits at 29% of that range, 43.5% below the 52-week high.
Oct 9, 2026 — TECX rises 2.5% to $23.33, 3 up days in a row
- Closed at $23.33, +2.55% vs the prior close of $22.75. Day range $22.74–$23.61, opened at $22.74.
- Volume was 110.70K shares, 0.5x its 50-day average of 235.01K — lighter than usual.
- Price is -21.0% vs its 50-day average ($29.53) and -16.9% vs its 200-day average ($28.07).
- 52-week range $15.32–$39.53; today's close sits at 33% of that range, 41.0% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — TECX ends flat (+0.2%) to $22.75
- Closed at $22.75, +0.18% vs the prior close of $22.71. Day range $21.59–$22.96, opened at $22.56.
- Volume was 167.70K shares, 0.7x its 50-day average of 234.96K.
- Price is -23.2% vs its 50-day average ($29.63) and -18.9% vs its 200-day average ($28.06).
- 52-week range $14.81–$39.53; today's close sits at 32% of that range, 42.4% below the 52-week high.
Oct 7, 2026 — TECX rises 1.3% to $22.71
- Closed at $22.71, +1.34% vs the prior close of $22.41. Day range $22.00–$23.43, opened at $22.23.
- Volume was 300.80K shares, 1.3x its 50-day average of 231.87K.
- Price is -23.7% vs its 50-day average ($29.75) and -19.0% vs its 200-day average ($28.04).
- 52-week range $14.60–$39.53; today's close sits at 33% of that range, 42.5% below the 52-week high.
Oct 6, 2026 — TECX slides 3.0% to $22.41, a 6-month low
- Closed at $22.41, -3.03% vs the prior close of $23.11. Day range $21.83–$23.27, opened at $23.15.
- Volume was 200.90K shares, 0.9x its 50-day average of 231.07K.
- Price is -25.0% vs its 50-day average ($29.89) and -20.0% vs its 200-day average ($28.02).
- 52-week range $14.60–$39.53; today's close sits at 31% of that range, 43.3% below the 52-week high.
Oct 5, 2026 — TECX rises 2.5% to $23.11
- Closed at $23.11, +2.53% vs the prior close of $22.54. Day range $21.71–$23.32, opened at $22.67.
- Volume was 312.60K shares, 1.4x its 50-day average of 226.80K.
- Price is -23.1% vs its 50-day average ($30.05) and -17.5% vs its 200-day average ($28.00).
- 52-week range $14.60–$39.53; today's close sits at 34% of that range, 41.5% below the 52-week high.
Oct 2, 2026 — TECX dips 0.6% to $22.54, a 6-month low, 14 down days in a row
- Closed at $22.54, -0.57% vs the prior close of $22.67. Day range $22.14–$23.07, opened at $22.73.
- Volume was 253.40K shares, 1.1x its 50-day average of 223.83K.
- Price is -25.4% vs its 50-day average ($30.20) and -19.4% vs its 200-day average ($27.98).
- 52-week range $14.60–$39.53; today's close sits at 32% of that range, 43.0% below the 52-week high.
- That makes 14 straight losses.
TECX latest news & SEC filings
Every SEC filing by or about TECX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Lochner Daniel had withheld for taxes 520 shares at $23.67 (≈$12.31K) on Sep 25, 2026; now holds 58,024
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Mcnamara Peter had withheld for taxes 444 shares at $23.67 (≈$10.51K) on Sep 25, 2026; now holds 54,841
- Mcnamara Peter sold 536 shares at $23.04 (≈$12.35K) on Sep 30, 2026; now holds 54,305
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Ruddy Marcella K. had withheld for taxes 525 shares at $23.67 (≈$12.43K) on Sep 25, 2026; now holds 67,157
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Reicin Alise had withheld for taxes 1,545 shares at $23.67 (≈$36.57K) on Sep 25, 2026; now holds 309,078
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Schwabish Marc had withheld for taxes 411 shares at $23.67 (≈$9.73K) on Sep 25, 2026; now holds 44,903
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 30, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$22.29M (prior year -$19.98M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$1.18 (prior year -$1.07) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade TECX
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 26, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.13% (largest 5.7%).
- Liquidity: about 244.34K shares (≈$5.05M) trade per day on average.
- 52-week position: $20.65 vs a range of $15.52–$39.53 (21% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Peter Mcnamara sold 43 shares on Aug 25, 2026.
- Latest filings: 8-K Sep 29, 2026; 10-Q Aug 6, 2026; 8-K Aug 6, 2026.
- Share count: 19.55M shares outstanding (Jul 31, 2026), +4.5% vs a year earlier.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
TECX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 21.35 | 21.51 | 20.55 | 20.65 | 175.42K |
| Oct 15, 2026 | 21.08 | 21.51 | 21.06 | 21.30 | 187.40K |
| Oct 14, 2026 | 21.22 | 21.75 | 20.60 | 20.96 | 190.80K |
| Oct 13, 2026 | 22.23 | 22.38 | 21.02 | 21.31 | 164.00K |
| Oct 12, 2026 | 22.99 | 23.12 | 22.26 | 22.35 | 103.90K |
| Oct 9, 2026 | 22.74 | 23.61 | 22.74 | 23.33 | 110.70K |
| Oct 8, 2026 | 22.56 | 22.96 | 21.59 | 22.75 | 167.70K |
| Oct 7, 2026 | 22.23 | 23.43 | 22.00 | 22.71 | 300.80K |
| Oct 6, 2026 | 23.15 | 23.27 | 21.83 | 22.41 | 200.90K |
| Oct 5, 2026 | 22.67 | 23.32 | 21.71 | 23.11 | 312.60K |
| Oct 2, 2026 | 22.73 | 23.07 | 22.14 | 22.54 | 253.40K |
| Oct 1, 2026 | 23.25 | 23.65 | 22.41 | 22.67 | 343.50K |
| Sep 30, 2026 | 23.66 | 23.66 | 22.60 | 23.29 | 251.60K |
| Sep 29, 2026 | 23.85 | 24.54 | 22.54 | 23.34 | 1.05M |
| Sep 28, 2026 | 23.54 | 23.99 | 23.13 | 23.51 | 234.80K |
| Sep 25, 2026 | 24.19 | 24.66 | 23.55 | 23.67 | 97.00K |
| Sep 24, 2026 | 24.85 | 24.86 | 23.06 | 24.12 | 214.40K |
| Sep 23, 2026 | 26.56 | 26.58 | 24.20 | 24.98 | 207.40K |
| Sep 22, 2026 | 26.83 | 27.58 | 26.21 | 26.50 | 188.60K |
| Sep 21, 2026 | 27.35 | 27.35 | 26.31 | 26.63 | 131.80K |
About Tectonic Therapeutic
Tectonic Therapeutic (TECX) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in WATERTOWN, MA. State of incorporation: NY. Fiscal year ends December 31. SEC CIK 1681087.
TECX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jessica Caroline Chutter | Director | Jun 10, 2026 |
| Phillip B. Donenberg | Director | Jun 10, 2026 |
| Francois Nader | Director | Apr 3, 2026 |
| Alise Reicin | Chief Executive Officer | Sep 8, 2026 |
| Timothy A Springer | Director | Jun 10, 2026 |
| Praveen P. Tipirneni | Director | Jun 10, 2026 |
| Stefan Vitorovic | Director | Jun 10, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Daniel Lochner | Chief Financial Officer | Sep 8, 2026 |
| Peter Mcnamara | Chief Scientific Officer | Sep 8, 2026 |
| Alise Reicin | Chief Executive Officer | Sep 8, 2026 |
| Marcella K. Ruddy | Chief Medical Officer | Sep 8, 2026 |
| Marc Schwabish | Chief Business Officer | Sep 8, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 25, 2026 | Peter Mcnamara | Sale | 43 | $36.52 |
| Aug 25, 2026 | Peter Mcnamara | Sale | 43 | $36.52 |
| Aug 25, 2026 | Peter Mcnamara | Sale | 43 | $36.52 |
| Aug 25, 2026 | Peter Mcnamara | Sale | 43 | $36.52 |
| Aug 12, 2026 | Peter Mcnamara | Sale | 43 | $35.00 |
| Aug 12, 2026 | Peter Mcnamara | Sale | 43 | $35.00 |
| Aug 12, 2026 | Peter Mcnamara | Sale | 43 | $35.00 |
| Aug 12, 2026 | Peter Mcnamara | Sale | 43 | $35.00 |
| Jun 30, 2026 | Peter Mcnamara | Sale | 172 | $35.00 |
| Jun 30, 2026 | Peter Mcnamara | Sale | 172 | $35.00 |
| Jun 30, 2026 | Peter Mcnamara | Sale | 172 | $35.00 |
| Jun 30, 2026 | Peter Mcnamara | Sale | 172 | $35.00 |
| May 4, 2026 | Marcella K. Ruddy | Sale | 1,065 | $30.00 |
| May 4, 2026 | Marcella K. Ruddy | Sale | 1,065 | $30.00 |
| May 4, 2026 | Marcella K. Ruddy | Sale | 1,065 | $30.00 |
TECX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-74.15M | -4.05 | $-60.08M |
| Dec 31, 2024 | — | $-57.98M | -6.83 | $-59.08M |
| Dec 31, 2023 | — | $-42.82M | -33.76 | $-40.68M |
| Dec 31, 2022 | — | $-105.89M | -2.42 | $-97.21M |
| Dec 31, 2021 | — | $-119.13M | -2.78 | $-98.03M |
Latest balance sheet: total assets $237.03M, total liabilities $13.19M, cash $227.07M (as of Jun 30, 2026).
TECX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $30.22 |
| May 7, 2026 | 8-K Item 2.02 (results) | $26.87 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $23.93 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $18.99 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $21.92 |
| May 8, 2025 | 8-K Item 2.02 (results) | $21.02 |
| Mar 20, 2025 | 8-K Item 2.02 (results) | $22.18 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $45.33 |
| Aug 14, 2024 | 8-K Item 2.02 (results) | — |
| Jun 20, 2024 | 8-K Item 2.02 (results) | — |
| May 11, 2023 | 8-K Item 2.02 (results) | — |
| Mar 23, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on TECX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.